C-Reactive Protein Testing Market Sees Rapid Growth Driven by Rising Chronic Disease Awareness

The global C-Reactive Protein (CRP) testing market is projected to grow from US$2.85 billion in 2025 to US$3.98 billion by 2032, at a compound annual growth rate (CAGR) of 4.9% during the forecast period. CRP testing plays an essential role in diagnosing and monitoring various inflammatory conditions, infections, and cardiovascular diseases. As the prevalence of chronic diseases increases and the demand for more accessible diagnostic solutions intensifies, the market for CRP testing is expanding globally. This article offers a detailed analysis of the current trends, challenges, and opportunities within the CRP testing market.

Overview of the C-Reactive Protein Testing Market

The C-Reactive Protein (CRP) testing market is integral to the healthcare sector as it enables the detection of inflammatory markers in the body. CRP is a protein produced by the liver in response to inflammation, and its levels can significantly rise in response to infections, chronic diseases, and cardiovascular events. The growing incidence of chronic diseases such as cardiovascular diseases (CVD), diabetes, and arthritis, combined with the increasing demand for point-of-care (POC) diagnostics, is spurring market growth. Additionally, technological advancements in immunoassay platforms and the adoption of high-sensitivity CRP (hs-CRP) tests are enhancing diagnostic precision and expanding market opportunities.

The CRP testing market is highly segmented, with key players offering a range of products and technologies, including immunoturbidimetry, lateral flow immunoassay, and enzyme-linked immunosorbent assay (ELISA). North America currently dominates the market, driven by its strong healthcare infrastructure and the early adoption of advanced CRP testing technologies. However, Asia Pacific is expected to exhibit the highest growth during the forecast period, largely due to increased healthcare access, growing demand for point-of-care diagnostics, and government initiatives aimed at improving diagnostic capabilities.

Key Highlights from the Report:

• North America is expected to hold over 36% of the market share in 2025.
• Asia Pacific is projected to grow at the fastest CAGR during the forecast period.
• The high-sensitivity CRP test is projected to dominate the market with a 42.5% share in 2025.
• Immunoturbidimetry is expected to be the leading assay technology, holding around 30% of the market share.
• The increasing adoption of point-of-care testing is contributing significantly to market growth.
• The rise of home healthcare services is driving demand for at-home CRP testing solutions.

Market Segmentation:

The CRP testing market is primarily segmented based on test type, assay technology, and end-user. Among these, the high-sensitivity CRP (hs-CRP) test is expected to lead the market. The hs-CRP test is pivotal in assessing cardiovascular risk and is widely used in preventive healthcare programs. This test helps in identifying individuals at risk of cardiovascular events and aids in early intervention through targeted treatment, such as statin therapy. Its dominance is attributed to its increasing inclusion in clinical guidelines for cardiovascular disease risk assessment, as well as its compatibility with automated laboratory systems.

Point-of-care testing (POCT) is another rapidly growing segment in the CRP testing market. POCT offers the advantage of delivering rapid results at the site of care, reducing the time needed for diagnosis and decision-making. These tests are particularly beneficial in emergency care settings, primary care, and urgent care clinics, where swift diagnosis is critical for effective treatment. As healthcare systems increasingly focus on decentralizing diagnostics, the adoption of POCT CRP testing is set to expand, especially in low-resource settings.

Regional Insights:

North America remains the largest market for CRP testing, accounting for over 36% of the global market share in 2025. The dominance of this region can be attributed to its robust healthcare infrastructure, high diagnostic spending, and the adoption of advanced diagnostic technologies in clinical practice. In addition, strong healthcare policies and guidelines, particularly in the U.S., which emphasize the use of hs-CRP tests in cardiovascular risk stratification, further drive market growth. Canada also contributes significantly to the region’s market share, with widespread use of CRP testing in routine health check-ups.

Asia Pacific is anticipated to be the fastest-growing region in the CRP testing market. The demand for CRP testing is rising in emerging economies like China, India, and Southeast Asia due to improving healthcare access, government-backed initiatives for infectious disease screening, and the increasing burden of chronic diseases. Point-of-care testing (POCT) is becoming a central focus in these countries, driven by the growing need for rapid diagnostics and the adoption of cost-effective testing solutions. Additionally, regulatory bodies in these regions are supporting the integration of CRP testing into routine healthcare practices, making it an attractive market for both established and new players.

Market Drivers:

Several factors are driving the growth of the CRP testing market. The most prominent driver is the increasing prevalence of chronic diseases such as cardiovascular disease, diabetes, and autoimmune disorders, all of which result in elevated CRP levels. As healthcare providers focus on early diagnosis and preventive care, CRP testing has gained significant traction. The rise of point-of-care testing has also played a crucial role in boosting market demand by providing quick, on-site results, reducing diagnostic waiting times, and facilitating rapid decision-making.

The growing awareness of preventive healthcare has further contributed to the expansion of CRP testing, as more individuals undergo regular screenings to detect potential health risks. Technological advancements in immunoassay platforms, including the development of high-sensitivity CRP tests, have improved the accuracy and reliability of CRP testing, making it an essential diagnostic tool. These advancements, combined with increased integration of CRP testing in routine check-ups, are enhancing its adoption across various healthcare settings.

Market Restraints:

Despite its growth potential, the CRP testing market faces some challenges. One of the key restraints is the limited specificity of CRP tests in distinguishing between bacterial and viral infections, particularly at low-to-moderate CRP concentrations. This can result in false positives, leading to overdiagnosis and unnecessary treatment, especially in cases of viral infections.

Moreover, performance variability across different CRP testing devices can lead to inconsistent results. This is particularly problematic in point-of-care testing (POCT) settings, where precision is critical for decision-making. Inaccurate CRP readings in decentralized environments may hinder the reliability of the test results and impact clinical workflows. Furthermore, pre-analytical instability and transport issues in remote CRP testing scenarios can also affect the overall accuracy of results, presenting another hurdle to market growth.

Market Opportunities

The CRP testing market holds several opportunities for growth, especially in the expanding field of telehealth and remote patient monitoring. The integration of CRP testing in telemedicine services presents significant potential for improving chronic disease management. Home-based CRP testing kits can help manage conditions like inflammatory bowel disease and rheumatoid arthritis, providing real-time data to healthcare providers and allowing for personalized treatment plans.

Additionally, the growth of microfluidic CRP testing devices, which are portable, cost-effective, and require minimal infrastructure, creates new opportunities for primary care outreach and community health screening in low-resource settings. The increasing demand for sepsis detection and antibiotic stewardship programs also presents a growing market for CRP-procalcitonin duplex tests, which can accelerate diagnosis in emergency care settings.

Reasons to Buy the Report

• Gain comprehensive insights into the market trends, drivers, and challenges influencing the CRP testing market.
• Understand the competitive landscape and key player strategies for market expansion.
• Identify the fastest-growing segments and the factors driving their growth.
• Leverage data to make informed decisions about investment in the CRP testing market.
• Evaluate regional opportunities and trends for entering emerging markets.

Frequently Asked Questions (FAQs):

• How Big is the C-Reactive Protein Testing Market?
• Who are the Key Players in the Global C-Reactive Protein Testing Market?
• What is the Projected Growth Rate of the C-Reactive Protein Testing Market?
• What is the Market Forecast for the C-Reactive Protein Testing Market in 2032?
• Which Region is Estimated to Dominate the C-Reactive Protein Testing Market through the Forecast Period?

Company Insights:

Key players operating in the C-Reactive Protein Testing Market include:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Beckman Coulter, Inc. (Danaher Corporation)
• Thermo Fisher Scientific Inc.
• Randox Laboratories Ltd.
• Ortho Clinical Diagnostics
• Quest Diagnostics Incorporated
• Bio-Rad Laboratories, Inc.
• Horiba, Ltd.
• Sysmex Corporation
• Tosoh Corporation
• DiaSorin S.p.A.
• Merck KGaA
• Becton, Dickinson and Company (BD)
• Abaxis, Inc. (Zoetis)
• Biosystems S.A.
• Genrui Biotech Inc.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Helena Laboratories Corporation

Recent Developments:

1. In May 2024, Radiometer launched the AQT90 FLEX immunoassay analyzer with CRP testing capabilities, providing results in under 13 minutes for emergency care settings.

2. In January 2024, Siemens HealthCare Diagnostics received FDA clearance for its Atellica CH High Sensitivity CRP 2 assay, allowing for quantitative CRP testing in serum and plasma.